Trials / Recruiting
RecruitingNCT06788652
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Lisocabtagene maraleucel | According to US Prescribing Information |
Timeline
- Start date
- 2025-02-04
- Primary completion
- 2044-09-30
- Completion
- 2044-09-30
- First posted
- 2025-01-23
- Last updated
- 2025-02-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06788652. Inclusion in this directory is not an endorsement.